Pfizer reports positive findings from new breast cancer drug trial

Pfizer has announced the findings of a new clinical trial showing the benefits that the investigational compound talazoparib can offer for people with breast cancer.

Data from the phase III EMBRACA trial has shown that patients with germline BRCA1/2-positive locally advanced and/or metastatic breast cancer demonstrated superior progression-free survival when treated with talazoparib compared to standard of care chemotherapy.

Median progression-free survival was 8.6 months for talazoparib, compared to 5.6 months for chemotherapy. This represents a 46 percent reduction in the risk of disease progression.

Additionally, the proportion of patients achieving a complete or partial response in the talazoparib group was shown to be more than twice that of the control arm. Data from this study will be used to support future regulatory approvals for the drug.

Dr Mace Rothenberg, chief development officer for oncology at Pfizer's global product development team, said: "By enrolling only patients with germline BRCA-positive metastatic breast cancer, treatment with talazoparib reduced the risk of disease worsening by nearly half, compared with current standard of care chemotherapy."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.